Oritavancin: A Long-Acting Antibacterial Lipoglycopeptide

References

• Guidance for Industry. Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment (2013). www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071185.pdf.
   Google Scholar
• Itani KM, Shorr AF. FDA guidance for ABSSSI trials: implications for conducting and interpreting clinical trials. Clin. Infect. Dis. 58 (Suppl. 1 ), S4 – S9 (2014).
   PubMedGoogle Scholar
• Guidance for Industry. Uncomplicated and Complicated Skin and Skin Structure Infections – Developing Antimicrobial Drugs for Treatment (1998). www.fda.gov/ohrms/dockets/98fr/2566dft.pdf.
   Google Scholar
• Edelsberg J, Taneja C, Zervos M et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg. Infect. Dis. 15 (9 ), 1516 – 1518 (2009).
   PubMed Web of Science ®Google Scholar
• Miller LG, Eisenberg DF, Liu H et al. Incidence of skin and soft tissue infections in ambulatory and inpatient settings, 2005–2010. BMC Infect. Dis. 15, 362 (2015).
   PubMed Web of Science ®Google Scholar
• Ray GT, Suaya JA, Baxter R. Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: a retrospective population-based study. BMC Infect. Dis. 13, 252 (2013).
   PubMed Web of Science ®Google Scholar
• Annual antimicrobial resistance surveillance in Europe 2014 (2015). http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2013.pdf.
   Google Scholar
• Lodise TP, Fan W, Sulham KA. Economic impact of oritavancin for the treatment of acute bacterial skin and skin structure infections in the emergency department or observation setting: cost savings associated with avoidable hospitalizations. Clin. Ther. 38 (1 ), 136 – 148 (2016).
   PubMed Web of Science ®Google Scholar
• Stevens DL, Bisno AL, Chambers HF et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin. Infect. Dis. 59 (2 ), 147 – 159 (2014).
   PubMed Web of Science ®Google Scholar
• Nunez-Nunez M, Rodriguez-Bano J. Dalbavancin or oritavancin for skin infections. N. Engl. J. Med. 371 (12 ), 1160 (2014).
   PubMedGoogle Scholar
• Nathwani D, Eckmann C, Lawson W et al. Pan-European early switch/early discharge opportunities exist for hospitalized patients with methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections. Clin. Microbiol. Infect. 20 (10 ), 993 – 1000 (2014).
   PubMed Web of Science ®Google Scholar
• Engel MF, Postma DF, Hulscher ME et al. Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP. Eur. Respir. J. 41 (1 ), 123 – 130 (2013).
   PubMed Web of Science ®Google Scholar
• Ramdeen S, Boucher HW. Dalbavancin for the treatment of acute bacterial skin and skin structure infections. Expert Opin. Pharmacother. 16 (13 ), 2073 – 2081 (2015).
   PubMed Web of Science ®Google Scholar
• Dunne MW, Puttagunta S, Giordano P, Krievins D, Zelasky M, Baldassarre J. A randomized clinical trial of single dose vs weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin. Infect. Dis. 62 (5 ), 545 – 551 (2016).
   PubMed Web of Science ®Google Scholar
• WHO Model List of Essential Medicine (2015). www.who.int/medicines/publications/essentialmedicines/en.
   Google Scholar
• Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: mechanism of action. Clin. Infect. Dis. 54 (Suppl. 3 ), S214 – S219 (2012).
   PubMedGoogle Scholar
• Belley A, Harris R, Beveridge T, Parr T Jr, Moeck G. Ultrastructural effects of oritavancin on methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus. Antimicrob. Agents Chemother. 53 (2 ), 800 – 804 (2009).
   PubMed Web of Science ®Google Scholar
• Kim SJ, Singh M, Schaefer J. Oritavancin binds to isolated protoplast membranes but not intact protoplasts of Staphylococcus aureus. J. Mol. Biol. 391 (2 ), 414 – 425 (2009).
   PubMed Web of Science ®Google Scholar
• McKay GA, Beaulieu S, Arhin FF et al. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J. Antimicrob. Chemother. 63 (6 ), 1191 – 1199 (2009).
   PubMed Web of Science ®Google Scholar
• Belley A, McKay GA, Arhin FF et al. Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing. Antimicrob. Agents Chemother. 54 (12 ), 5369 – 5371 (2010).
   PubMed Web of Science ®Google Scholar
• Morrissey I, Seifert H, Canton R et al. Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and beta-haemolytic streptococci collected from western European countries in 2011. J. Antimicrob. Chemother. 68 (1 ), 164 – 167 (2013).
   PubMed Web of Science ®Google Scholar
• Biedenbach DJ, Arhin FF, Moeck G, Lynch TF, Sahm DF. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011–2014. Int. J. Antimicrob. Agents 46 (6 ), 674 – 681 (2015).
   PubMed Web of Science ®Google Scholar
• Jones RN, Turnidge JD, Moeck G, Arhin FF, Mendes RE. Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide. Antimicrob. Agents Chemother. 59 (4 ), 2405 – 2409 (2015).
   PubMed Web of Science ®Google Scholar
• Garcia LG, Lemaire S, Kahl BC et al. Pharmacodynamic evaluation of the activity of antibiotics against hemin- and menadione-dependent small-colony variants of Staphylococcus aureus in models of extracellular (broth) and intracellular (THP-1 monocytes) infections. Antimicrob. Agents Chemother. 56 (7 ), 3700 – 3711 (2012).
   PubMed Web of Science ®Google Scholar
• Belley A, Neesham-Grenon E, McKay G et al. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrob. Agents Chemother. 53 (3 ), 918 – 925 (2009).
   PubMed Web of Science ®Google Scholar
• Arhin FF, Sarmiento I, Belley A et al. Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrob. Agents Chemother. 52 (5 ), 1597 – 1603 (2008).
   PubMed Web of Science ®Google Scholar
• Mendes RE, Farrell DJ, Sader HS, Jones RN. Oritavancin microbiologic features and activity results from the surveillance program in the United States. Clin. Infect. Dis. 54 (Suppl. 3 ), S203 – S213 (2012).
   PubMed Web of Science ®Google Scholar
• M07-A10: Methods for Dilution Antimicrobial susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard 10th Edition (2015).
   Google Scholar
• Clinical Breakpoints (2016). www.eucast.org/clinical_breakpoints.
   Google Scholar
• Oritavancin. Full Prescribing information (2016). www.accessdata.fda.gov/drugsatfda_docs/label/2014/206334s000lbl.pdf.
   Google Scholar
• Saravolatz LD, Pawlak J, Johnson LB. In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA). Int. J. Antimicrob. Agents 36 (1 ), 69 – 72 (2010).
   PubMed Web of Science ®Google Scholar
• Lin G, Pankuch G, Appelbaum PC, Kosowska-Shick K. Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents. Antimicrob. Agents Chemother. 58 (10 ), 6251 – 6254 (2014).
   PubMed Web of Science ®Google Scholar
• Sader HS, Flamm RK, Farrell DJ, Jones RN. Daptomycin activity against uncommonly isolated streptococcal and other gram-positive species groups. Antimicrob. Agents Chemother. 57 (12 ), 6378 – 6380 (2013).
   PubMed Web of Science ®Google Scholar
• Mendes RE, Woosley LN, Farrell DJ, Sader HS, Jones RN. Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009–2010. Antimicrob. Agents Chemother. 56 (3 ), 1639 – 1642 (2012).
   PubMed Web of Science ®Google Scholar
• Mendes RE, Farrell DJ, Sader HS, Flamm RK, Jones RN. Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010–2013). J. Antimicrob. Chemother. 70 (2 ), 498 – 504 (2015).
   PubMed Web of Science ®Google Scholar
• Citron DM, Kwok YY, Appleman MD. In vitro activity of oritavancin (LY333328), vancomycin, clindamycin, and metronidazole against Clostridium perfringens, Propionibacterium acnes, and anaerobic Gram-positive cocci. Anaerobe 11 (1–2 ), 93 – 95 (2005).
   PubMed Web of Science ®Google Scholar
• O'Connor R, Baines SD, Freeman J, Wilcox MH. In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin. J. Antimicrob. Chemother. 62 (4 ), 762 – 765 (2008).
   PubMed Web of Science ®Google Scholar
• Biavasco F, Vignaroli C, Lupidi R, Manso E, Facinelli B, Varaldo PE. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide. Antimicrob. Agents Chemother. 41 (10 ), 2165 – 2172 (1997).
   PubMed Web of Science ®Google Scholar
• Belley A, Neesham-Grenon E, Arhin FF, McKay GA, Parr TR Jr, Moeck G. Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob. Agents Chemother. 52 (10 ), 3820 – 3822 (2008).
   PubMed Web of Science ®Google Scholar
• Nguyen HA, Denis O, Vergison A et al. Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains. Antimicrob. Agents Chemother. 53 (4 ), 1434 – 1442 (2009).
   PubMed Web of Science ®Google Scholar
• Smith JR, Yim J, Raut A, Rybak MJ. Oritavancin combinations with beta-lactams against multidrug-resistant Staphylococcus aureus and vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 60 (4 ), 2352 – 2358 (2016).
   PubMed Web of Science ®Google Scholar
• Lefort A, Saleh-Mghir A, Garry L, Carbon C, Fantin B. Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis. Antimicrob. Agents Chemother. 44 (11 ), 3017 – 3021 (2000).
   PubMed Web of Science ®Google Scholar
• Rubino CM, Van Wart SA, Bhavnani SM, Ambrose PG, McCollam JS, Forrest A. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrob. Agents Chemother. 53 (10 ), 4422 – 4428 (2009).
   PubMed Web of Science ®Google Scholar
• Rubino CM, Bhavnani SM, Moeck G, Bellibas SE, Ambrose PG. Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal Phase 3 clinical trials. Antimicrob. Agents Chemother. 59 (6 ), 3365 – 3372 (2015).
   PubMed Web of Science ®Google Scholar
• Ghosh M. Medical Review (2013). www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206334Orig1s000MedR.pdf.
   Google Scholar
• Briefing Document for the Anti-Infective Drugs Advisory Committee: NUVOCID® (oritavancin diphosphate for injection) for Treatment of Complicated Skin and Skin Structure Infections (NDA 22–153) (2008). www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4394b2-04-Targanta.pdf.
   Google Scholar
• Dunbar LM, Milata J, McClure T, Wasilewski MM. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrob. Agents Chemother. 55 (7 ), 3476 – 3484 (2011).
   PubMed Web of Science ®Google Scholar
• Corey GR, Kabler H, Mehra P et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N. Engl. J. Med. 370 (23 ), 2180 – 2190 (2014).
   PubMed Web of Science ®Google Scholar
• Corey GR, Good S, Jiang H et al. Single-dose oritavancin versus 7–10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin. Infect. Dis. 60 (2 ), 254 – 262 (2015).
   PubMed Web of Science ®Google Scholar
• Arhin FF, Belley A, McKay G et al. Assessment of oritavancin serum protein binding across species. Antimicrob. Agents Chemother. 54 (8 ), 3481 – 3483 (2010).
   PubMed Web of Science ®Google Scholar
• Van Bambeke F, Carryn S, Seral C et al. Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrob. Agents Chemother. 48 (8 ), 2853 – 2860 (2004).
   PubMed Web of Science ®Google Scholar
• Fetterly GJ, Ong CM, Bhavnani SM et al. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob. Agents Chemother. 49 (1 ), 148 – 152 (2005).
   PubMed Web of Science ®Google Scholar
• Bhavnani SM, Owen JS, Loutit JS, Porter SB, Ambrose PG. Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn. Microbiol. Infect. Dis. 50 (2 ), 95 – 102 (2004).
   PubMed Web of Science ®Google Scholar
• Briefing Document for the Anti-Infective Drugs Advisory Committee (2008). www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4394b2-04-Targanta.pdf.
   Google Scholar
• Kumar A, Mann HJ, Keshtgarpour M et al. In vitro characterization of oritavancin clearance from human blood by low-flux, high-flux, and continuous renal replacement therapy dialyzers. Int. J. Artif. Organs 34 (11 ), 1067 – 1074 (2011).
   PubMed Web of Science ®Google Scholar
• Boylan CJ, Campanale K, Iversen PW, Phillips DL, Zeckel ML, Parr TR Jr. Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrob. Agents Chemother. 47 (5 ), 1700 – 1706 (2003).
   PubMed Web of Science ®Google Scholar
• Ambrose PG, Drusano GL, Craig WA. In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans. Clin. Infect. Dis. 54 (Suppl. 3 ), S220 – S228 (2012).
   PubMed Web of Science ®Google Scholar
• Rupp ME, Fey PD, Longo GM. Effect of LY333328 against vancomycin-resistant Enterococcus faecium in a rat central venous catheter-associated infection model. J. Antimicrob. Chemother. 47 (5 ), 705 – 707 (2001).
   PubMed Web of Science ®Google Scholar
• Kaatz GW, Seo SM, Aeschlimann JR, Houlihan HH, Mercier RC, Rybak MJ. Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 42 (4 ), 981 – 983 (1998).
   PubMed Web of Science ®Google Scholar
• Saleh-Mghir A, Lefort A, Petegnief Y et al. Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis. Antimicrob. Agents Chemother. 43 (1 ), 115 – 120 (1999).
   PubMed Web of Science ®Google Scholar
• Gerber J, Smirnov A, Wellmer A et al. Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin. Antimicrob. Agents Chemother. 45 (7 ), 2169 – 2172 (2001).
   PubMed Web of Science ®Google Scholar
• Cabellos C, Fernandez A, Maiques JM et al. Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis. Antimicrob. Agents Chemother. 47 (6 ), 1907 – 1911 (2003).
   PubMed Web of Science ®Google Scholar
• Heine HS, Bassett J, Miller L et al. Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax. Antimicrob. Agents Chemother. 52 (9 ), 3350 – 3357 (2008).
   PubMed Web of Science ®Google Scholar
• Freeman J, Marquis M, Crowther GS et al. Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model. J. Antimicrob. Chemother. 67 (12 ), 2919 – 2926 (2012).
   PubMed Web of Science ®Google Scholar
• Johnson JA, Feeney ER, Kubiak DW, Corey GR. Prolonged use of oritavancin for vancomycin-resistant Enterococcus faecium prosthetic valve endocarditis. Open Forum Infect. Dis. 2 (4 ), ofv156 (2015).
   PubMedGoogle Scholar
• Summary of the risk management plan (RMP) for Orbactiv (2015). www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Risk-management-plan_summary/human/003785/WC500180547.pdf.
   Google Scholar
• NDA206–334 Deputy Division Director Summary Memo (2014). www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206334Orig1s000SumR.pdf.
   Google Scholar
• Lehoux D, Ostiguy V, Cadieux C et al. Oritavancin pharmacokinetics and bone penetration in rabbits. Antimicrob. Agents Chemother. 59 (10 ), 6501 – 6505 (2015).
   PubMed Web of Science ®Google Scholar